Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 139262-20-7 | MDL No. : | MFCD01862677 |
Formula : | C20H19NO5 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | GOUUPUICWUFXPM-KPZWWZAWSA-N |
M.W : | 353.37 | Pubchem ID : | 7408199 |
Synonyms : |
|
Num. heavy atoms : | 26 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.3 |
Num. rotatable bonds : | 5 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 97.84 |
TPSA : | 87.07 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.77 cm/s |
Log Po/w (iLOGP) : | 2.06 |
Log Po/w (XLOGP3) : | 2.38 |
Log Po/w (WLOGP) : | 2.07 |
Log Po/w (MLOGP) : | 1.97 |
Log Po/w (SILICOS-IT) : | 1.76 |
Consensus Log Po/w : | 2.05 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -3.54 |
Solubility : | 0.101 mg/ml ; 0.000287 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.85 |
Solubility : | 0.05 mg/ml ; 0.000141 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.79 |
Solubility : | 0.0572 mg/ml ; 0.000162 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.79 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
67% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
63% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
74% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
65% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
57% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
50% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
6.1 (1) (1) Synthesis of Fmoc-D-Hyp-OH 262 mg (2.0 mmol) of D-Hyp-OH was dissolved in 5 ml of a saturated aqueous solution of sodium hydrogencarbonate under stirring and a mixture of 742 mg (2.2 mmol) of Fmoc-OSu and 10 ml of 1,4-dioxane was added dropwise under cooling with ice; thereafter, and the mixture was stirred at room temperature for 3 days. In the meantime, a saturated aqueous solution of sodium hydrogencarbonate was added as appropriate to keep the pH of the reaction mixture at 8-9. After being rendered acidic with hydrochloric acid under cooling with ice, the reaction mixture was subjected to extraction with ethyl acetate. The ethyl acetate layer was washed with water and saturated brine, dried with anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (eluding solvents were chloroform and acetic acid supplemented chloroform:methanol=10:1); to remove the acetic acid used in eluding, the fractions were once concentrated under reduced pressure and dissolved again in ethyl acetate; thereafter, the solution was washed with water, dried with anhydrous magnesium sulfate and concentrated under reduced pressure to give a colorless powder in the amount of 660 mg (93%). NMR(method g,DMSO-d6): δ 1.89-2.29(2H,m), 3.26-3.56(3H,m), 4.10-4.47(4H,m), 5.15(1H,brs), 7.28-7.94(8H,m), 12.64(1H,brs). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: L-Asn(Trt) With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide Automated synthesizer; Stage #2: With piperidine In N,N-dimethyl-formamide Automated synthesizer; Stage #3: acetic anhydride; Fmoc-Tyr(tBu)-OH; Fmoc-Thr(tBu)-OH; N-Fmoc 4-hydroxypropline Further stages; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: Fmoc-D-arginine With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide for 1h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.333333h; Stage #3: C11H6BrClN2OS; 6-[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoic acid; N-Fmoc 4-hydroxypropline; Fmoc-D-arginine Further stages; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: Fmoc-D-arginine With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide for 1h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.333333h; Stage #3: C11H6BrClN2OS; 6-[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoic acid; N-Fmoc 4-hydroxypropline; Fmoc-D-arginine Further stages; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: Fmoc-D-arginine With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide for 1h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.333333h; Stage #3: C11H6BrClN2OS; 6-[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoic acid; N-Fmoc 4-hydroxypropline; Fmoc-D-arginine Further stages; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: Fmoc-D-arginine With 4-methyl-morpholine; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate In N,N-dimethyl-formamide for 1h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.333333h; Stage #3: C11H6BrClN2OS; N-Fmoc 4-hydroxypropline; Fmoc-D-arginine Further stages; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |